Chedid M, Michieli P, Lengel C, Huppi K, Givol D
Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892.
Oncogene. 1994 Oct;9(10):3021-4.
The recently discovered WAF1/CIP1 gene is a mediator of p53 tumor suppressor activity. To analyse WAF1/CIP1 for possible mutations, polymerase chain reaction (PCR) amplified cDNAs from several tumor cell lines were cloned and sequenced. A single point mutation which changes codon 31 from AGC to AGA (Ser to Arg) was found. This change resulted in the loss of a Bpu1102I and gain of an Esp3I restriction site, allowing for rapid screening of this mutation in human DNAs. Analysis of genomic DNAs from 50 randomly selected individuals revealed that this base pair substitution represents a polymorphism with an allelic frequency of 0.14. Transfection studies demonstrated that the expression of the Arg allele of WAF1/CIP1 was not associated with loss of tumor suppressor activity. Moreover, screening of 22 tumor DNA samples revealed no association between the tumor phenotype and the Arg allele of WAF1/CIP1 (two out of 22 tumor DNAs contained the Arg31 allele). This polymorphism will be a useful molecular marker in the analysis of loss of heterozygosity in human cancers, and further studies using a larger panel of tumors may reveal an association between this polymorphism and specific types of cancer.
最近发现的WAF1/CIP1基因是p53肿瘤抑制活性的介导因子。为了分析WAF1/CIP1是否存在可能的突变,对来自几种肿瘤细胞系的聚合酶链反应(PCR)扩增的cDNA进行了克隆和测序。发现了一个单点突变,该突变将密码子31从AGC变为AGA(丝氨酸变为精氨酸)。这种变化导致Bpu1102I限制性酶切位点的丢失和Esp3I限制性酶切位点的获得,从而能够在人类DNA中快速筛选该突变。对50个随机选择个体的基因组DNA分析表明,这种碱基对替换代表一种多态性,其等位基因频率为0.14。转染研究表明,WAF1/CIP1精氨酸等位基因的表达与肿瘤抑制活性的丧失无关。此外,对22个肿瘤DNA样本的筛选显示,肿瘤表型与WAF1/CIP1精氨酸等位基因之间没有关联(22个肿瘤DNA中有两个含有精氨酸31等位基因)。这种多态性将是分析人类癌症杂合性缺失的一个有用分子标记,使用更多肿瘤样本的进一步研究可能会揭示这种多态性与特定癌症类型之间的关联。